HTRF® cell-based phospho and total-STAT3 assays for anti-cancer research
In response to cytokines and growth factors, STAT3, Signal transducer and activator of transcription 3 is phosphorylated at Tyr705 by activation of JAK proteins, or by various receptor tyrosine kinases. STAT3 has been found to be upregulated in many cancers including glioblastoma, head and neck cancer, prostate cancer, and breast cancer. A constitutively active form of STAT3 is oncogenic. STAT 3 activation is associated with Crohn's disease, and other inflammatory diseases such as pulmonary fibrosis and acute lung injury. STAT3 is critical for leptin signaling and its mutation leads to obesity in mice.
Cisbio’s homogeneous and robust HTRF® phospho-STAT3 (Tyr705) assay kit is designed for the cell-based quantitative detection of STAT3 signaling activity. The HTRF® total STAT3 assay kit is designed for the quantitative detection of total STAT3, phosphorylated and unphosphorylated, to normalize the phosphorylation status of STAT3 with respect to its steady-state level in cells.
The buffers of both HTRF® phospho- and total STAT3 assays are compatible, enabling an analysis of the phosphorylated and the total protein populations from one lysate sample.